Eli Lilly developed by the world’s first company, It is the only existing drug treatment of malignant pleural mesothelioma — ALIMTA (Alimta). officially listed in China. According to reports, Eli Lilly ALIMTA is the latest contribution in the field of cancer therapy. Pleural mesothelioma is a landmark in the field of treatment progress The medical profession has been widely acclaimed as a global “refractory cancer breakthroughs.” Due to its unique effect. The United States Food and Drug Administration (FDA) in February 2004 for rapid approval of the drug for a rare form of the disease than that approved Thailand (Alimta) for the first line treatment of advanced malignant pleural mesothelioma drug to be the first to be approved, but only for the treatment of advanced malignant pleural mesothelioma current drugs. China’s Food and Drug Administration has fast-track approval, the approval of its listing in China. ALIMTA cancer survival is very important to be able to block at least three different enzymes. It extended the survival time of patients, significant improvements in the quality of life. Meanwhile, folic acid and vitamin supplement to effectively control drug reactions, increase the tolerance of patients. Currently, ALIMTA in more than 60 countries around the world have listed, sales in 2004 alone amounted to more than 140 million U.S. dollars to fully prove its efficacy and safety. In the treatment of malignant pleural mesothelioma. ALIMTA international medical circles generally believe this could become the standard treatment of refractory cancer drug. Malignant pleural mesothelioma is a rare lung cancer of the pleura, the main causes of asbestos direct and indirect contacts. Nianqiandang many have yet to understand the dangers of asbestos, many transportation, Insulation and the mining industry through exposure to asbestos fibers, but it is not only direct contact with asbestos. Reports indicate the overalls through contact relatives also indirectly exposed to asbestos to the families of malignant pleural mesothelioma. About 80% of cases attributable to asbestos exposure in the etiology of history and the incubation period may be as long as 20 to 40 years. Most patients to be diagnosed late stage, not general surgery or radiotherapy. With the asbestos industry, the increasing incidence of mesothelioma. Generally, the disease incidence in 30 to 40 years after exposure to asbestos, and the peak incidence is often late, peak around is different. The incidence peaks in the United States in 2010, the peak incidence in Europe for the past 2020 years. Although the ratio of China’s industrial development asbestos far below European countries, but China still is the production of asbestos, asbestos products are being widely used. imagine how the arrival of the peak. However, China has yet to carry out the use of asbestos exposure and the national investigation in an effort to end, China Association of lung cancer professionals vice chairman of the committee, Shanghai Chest Hospital, Professor Liao Meilin urged state departments should carry out this investigation, for effective early intervention and prevention. In the United States and the European Union, ALIMTA rapid processing methods were also approved for the second-line treatment of non-small cell lung cancer. Meanwhile, ALIMTA as a first-line treatment of non-small cell lung cancer and small-cell lung cancer, breast cancer and cancer. ovarian cancer and stomach cancer treatment being studied. Eli Lilly Company is ALIMTA Chuan Shih Chinese scientists will join forces with the United States Department of Chemistry, Princeton University, after more than 10 years of research and the successful development of the study. As research and development of innovative drugs pharmaceutical companies, Eli Lilly Corporation in the United States, “the best development of similar products. Drugs first developed or services for patients “as their own task. worked very hard to explore various intractable diseases that afflict humanity, the advanced treatment methods. According to reports, the ceremony will invest a lot of capital to companies for research and development. Eli Lilly company’s sales in 2004 reached 13.8 billion U.S. dollars and 2.7 billion U.S. dollars for R & D investment. accounted for 19% of total sales, daily input for the development of new drugs for 10.4 million U.S. dollars. Such a high proportion of investment in the pharmaceutical industry is a leading industry average of 15%. ALIMTA ceremony to be introduced this year in the Chinese market and one of the four new products, the rate of introduction of new drugs in China by multinational pharmaceutical companies are especially noteworthy. The next five years, Eli Lilly plans to have 15 drugs listed one after another in China, which covers central nervous system, diabetes, cancer, injection equipment, pediatric ADHD and other fields. ALIMTA listed in the press conference, Dr. Eli Lilly Outaige Chinese president also announced that Eli Lilly Company from China in 2006 began to enter a new round of rapid expansion. 2006 Eli Lilly in cancer and diabetes will increase 100% of the area of new jobs In 2010 the number of staff will be around to expand from the current 700 to 1,000 people. Dr. Outaige said : “tumor area is one of the ceremony’s traditional strengths. We will continue to accelerate the pace of the introduction of the new drug benefit of the Chinese patients. “According to information, Eli Lilly compounds in the present study, 50% of the compounds in the tumor area.